CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. Dermatofibrosarcoma protuberans of the face. CD34 immunoreactivity distinguishes between scar tissue and residual tumor in re-excisional specimens of dermatofibrosarcoma protuberans. Medicine is a constantly changing science and not all therapies are clearly established.
New research changes drug and treatment therapies daily.
However, as medical science is constantly changing and human error is always possible , the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. Dermatofibrosarcoma Protuberans Please email us with any comments you have on our new chapter format.